Management of Parkinson's disease in older women

Menopause International

Volumn 14, Issue 1, 2008, Pages 38-39

  Price, Molly Daymont ^a   Shulman, Lisa M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Ageing; Estrogen; Levodopa; Parkinson's disease; Women

Indexed keywords

BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CONJUGATED ESTROGEN; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; ANTIPARKINSON AGENT;

BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; COGNITION; DYSKINESIA; ESTROGEN THERAPY; HUMAN; MONOTHERAPY; PARKINSON DISEASE; QUALITY OF LIFE; SEX DIFFERENCE; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; AGED; ARTICLE; FEMALE; MALE; SEX RATIO;

AGED; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; PARKINSON DISEASE; SEX DISTRIBUTION;

EID: 47249095840     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/mi.2007.007038     Document Type: Short Survey

References (14)

1. Levy G. The relationship of Parkinson's disease with aging. Arch Neurol 2007;64:1242-1246
2. Silver D. Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 2006;12:214-223 (Pubitemid 44134047)
3. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 2000;15:664-668 (Pubitemid 30479618)
4. Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, et al. Does ageing influence deep brain stimulation outcomes in Parkinson's disease? Mov Disord 2007;22:1457-1463
5. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:819-824
6. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton Iii LJ. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2007; [Epub ahead of print]
7. Currie LJ, Harrison MV, Trugman JM, et al. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-888 (Pubitemid 38747327)
8. Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292-2298 (Pubitemid 30416280)
9. Nicoletti A, Arabia G, Pugliese P, et al. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin Neuropharmacol 2007;30:276-280 (Pubitemid 47511507)
10. Arabia G, Zappia M, Bosco D, et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 2002;23:S53-4 (Pubitemid 35355773)
11. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the WHI randomized control trial. JAMA 2004;291:1701-1712
12. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333 (Pubitemid 34761611)
13. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477 (Pubitemid 46556472)
14. Shulman LM, Bhat V. Gender disparities in Parkinson's disease. Expert Rev Neurotherapeutics 2006;6:407-416